Clinic Roundup

• BrainStorm Cell Therapeutics Inc., of New York, began treating its first patient in a Phase IIa trial of its stem cell therapy in amyotrophic lateral sclerosis. Three groups of four patients will be treated with intramuscular and intrathecal administration of NurOwn cells, in increasing doses.